EXACT Sciences Corporation Is a Sell; Strong Momentum from Option Traders


 EXACT Sciences Corporation Is a Sell; Strong Momentum from Option Traders

In today’s session EXACT Sciences Corporation (EXAS) recorded an unusually high (201) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the January, 2018 put, expecting serious EXAS decrease. With 201 contracts traded and 2104 open interest for the Jan, 18 contract, it seems this is a quite bearish bet. The option with symbol: EXAS180119P00013000 closed last at: $2.25 or 0% . The stock decreased 0.21% or $0.04 during the last trading session, hitting $18.81. About 2.42 million shares traded hands. EXACT Sciences Corporation (NASDAQ:EXAS) has risen 248.33% since March 2, 2016 and is uptrending. It has outperformed by 239.09% the S&P500.

Analysts await EXACT Sciences Corporation (NASDAQ:EXAS) to report earnings on November, 3. They expect $-0.44 EPS, up 2.22% or $0.01 from last year’s $-0.45 per share. After $-0.46 actual EPS reported by EXACT Sciences Corporation for the previous quarter, Wall Street now forecasts -4.35% EPS growth.

EXACT Sciences Corporation (NASDAQ:EXAS) Ratings Coverage

Out of 13 analysts covering EXACT Sciences (NASDAQ:EXAS), 5 rate it a “Buy”, 1 “Sell”, while 7 “Hold”. This means 38% are positive. EXACT Sciences has been the topic of 25 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Friday, October 30 by Roth Capital. Lake Street maintained the stock with “Hold” rating in Tuesday, November 24 report. Lake Street downgraded EXACT Sciences Corporation (NASDAQ:EXAS) rating on Wednesday, October 7. Lake Street has “Hold” rating and $16 price target. Canaccord Genuity maintained the stock with “Buy” rating in Monday, August 24 report. The firm has “Buy” rating given on Tuesday, October 6 by Roth Capital. On Wednesday, July 27 the stock rating was maintained by Jefferies with “Buy”. As per Tuesday, July 21, the company rating was maintained by Benchmark. The rating was initiated by BTIG Research with “Buy” on Friday, December 18. The stock has “Buy” rating given by Jefferies on Thursday, February 25. Mizuho downgraded EXACT Sciences Corporation (NASDAQ:EXAS) on Wednesday, May 4 to “Neutral” rating.

Insitutional Activity: The institutional sentiment increased to 1.42 in 2016 Q2. Its up 0.70, from 0.72 in 2016Q1. The ratio increased, as 18 funds sold all EXACT Sciences Corporation shares owned while 41 reduced positions. 30 funds bought stakes while 54 increased positions. They now own 87.89 million shares or 11.45% more from 78.86 million shares in 2016Q1.
Guggenheim Cap Ltd Limited Liability Company last reported 0.01% of its portfolio in the stock. Friess Associates Ltd accumulated 54,000 shares or 0.07% of the stock. Weiss Multi last reported 10,935 shares in the company. Cap Ww Investors reported 1.75 million shares or 0.01% of all its holdings. Moreover, Oxbow Advsr Ltd Limited Liability Company has 0.02% invested in EXACT Sciences Corporation (NASDAQ:EXAS) for 10,000 shares. Blackrock Advsrs Lc owns 83,730 shares or 0% of their US portfolio. Balyasny Asset Management Limited Com has 0.07% invested in the company for 835,000 shares. Ladenburg Thalmann Service holds 0% or 5,586 shares in its portfolio. Raymond James & Associate last reported 0.01% of its portfolio in the stock. J&P(China)Capital Mngmt Coltd holds 4.94% or 1.25M shares in its portfolio. The Kansas-based Financial Advisory Incorporated has invested 0.05% in EXACT Sciences Corporation (NASDAQ:EXAS). Wells Fargo Mn has invested 0% of its portfolio in EXACT Sciences Corporation (NASDAQ:EXAS). Blair William & Il accumulated 559,938 shares or 0.06% of the stock. Comml Bank Of New York Mellon Corporation accumulated 0% or 434,230 shares. Rhumbline Advisers accumulated 0% or 106,088 shares.

Insider Transactions: Since July 25, 2016, the stock had 2 insider purchases, and 2 selling transactions for $67,363 net activity. 5,000 shares were bought by Sterling Lionel, worth $90,500 on Thursday, September 1. $60,613 worth of EXACT Sciences Corporation (NASDAQ:EXAS) was bought by Zanotti Katherine S on Wednesday, August 3. $109,416 worth of EXACT Sciences Corporation (NASDAQ:EXAS) was sold by LIDGARD GRAHAM PETER. ARORA MANEESH sold 7,359 shares worth $109,060.

Exact Sciences Corporation is a molecular diagnostics firm focused on the early detection and prevention of some forms of cancer. The company has a market cap of $2.04 billion. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline. It currently has negative earnings. It has developed a non invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply